Boston Common Asset Management LLC Has $28.26 Million Stake in AstraZeneca PLC (OTCMKTS:AZNCF)

Boston Common Asset Management LLC lessened its stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) by 17.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 216,775 shares of the company’s stock after selling 45,498 shares during the period. AstraZeneca accounts for 0.8% of Boston Common Asset Management LLC’s portfolio, making the stock its 24th largest holding. Boston Common Asset Management LLC’s holdings in AstraZeneca were worth $28,257,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Eagle Bay Advisors LLC acquired a new position in AstraZeneca during the 3rd quarter valued at $156,000. 40.87% of the stock is currently owned by institutional investors.

AstraZeneca Stock Performance

Shares of OTCMKTS:AZNCF traded up $2.37 on Friday, hitting $132.13. 1,869 shares of the company were exchanged, compared to its average volume of 2,777. The company’s 50 day moving average price is $131.41 and its two-hundred day moving average price is $148.22. AstraZeneca PLC has a one year low of $118.16 and a one year high of $175.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.